(Q30379568)

21 June 2017

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03. (English)

1 reference

21 June 2017

0 references

0 references

Takeshi Naruse

1

1 reference

21 June 2017

Tadashi Fukuda

2

1 reference

21 June 2017

Tetsuro Tanabe

3

1 reference

21 June 2017

Munetaka Ichikawa

4

1 reference

21 June 2017

Yoshiaki Oda

5

1 reference

21 June 2017

Shinji Tochihara

6

1 reference

21 June 2017

Kazuhiko Kimachi

7

1 reference

21 June 2017

Yoichiro Kino

8

1 reference

21 June 2017

Kohji Ueda

9

1 reference

21 June 2017

language of work or name

English

0 references

publication date

23 September 2015

1 reference

21 June 2017

1 reference

21 June 2017

33

1 reference

21 June 2017

6078-6084

1 reference

21 June 2017

45

1 reference

describes a project that uses

21 June 2017

EB66

0 references

cites work

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Characterization of a whole, inactivated influenza (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Current status and progress of prepandemic and pandemic influenza vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.022

10.1016/J.VACCINE.2015.09.022

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference